RACHELLE DOODY to Magnetic Resonance Imaging
This is a "connection" page, showing publications RACHELLE DOODY has written about Magnetic Resonance Imaging.
Connection Strength
0.536
-
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 01; 82(1):19-29.
Score: 0.426
-
Does APO epsilon4 correlate with MRI changes in Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2000 Nov; 69(5):668-71.
Score: 0.020
-
Statistical Model of Dynamic Markers of the Alzheimer's Pathological Cascade. J Gerontol B Psychol Sci Soc Sci. 2018 08 14; 73(6):964-973.
Score: 0.017
-
Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data. J Alzheimers Dis. 2017; 58(2):361-371.
Score: 0.015
-
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017; 58(4):1217-1228.
Score: 0.015
-
Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016 07; 28:41-48.
Score: 0.015
-
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010 Mar 23; 74(12):956-64.
Score: 0.010
-
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 Dec 15; 73(24):2061-70.
Score: 0.009
-
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66.
Score: 0.006
-
Progressive nonfluent aphasia with dementia: a case report. J Geriatr Psychiatry Neurol. 1991 Oct-Dec; 4(4):236-40.
Score: 0.003